Clinical trials: Gastric Neoplasm
Perioperative Neurocognitive Disorders, Gastric Cancer
Effect of Gastrectomy on Gut Microbiome and Cognitive Function
Perioperative neurocognitive disorders is a common postoperative complication in elderly surgical patients. The role of gut microbiota in cognitive function has been concerned in recent years.
- Trial name
- NCT06186089
- Testing
- probiotics
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiangjiang Bi
Overall Survival
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
This study is to conduct a randomized controlled trial of two kinds of radical gastrectomy for patients with proximal gastric cancer.
- Trial name
- NCT04050787
- Testing
- D2 Lymphadenectomy including No. 10, D2 lymphadenectomy excluding No. 10
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Suo
Gastric Outlet Obstruction
Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction
The purpose of this study is to determine if the Cook Magnetic Anastomosis Device can be used to safely and successfully create a patent gastrojejunal anastomosis in subjects requiring treatment of gastric outlet obstruction…
- Trial name
- MAD (NCT00487552)
- Testing
- Cook Magnetic Anastomosis Device (MAD) with Stent
- Where
- 4 sites in Belgium, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Cook Group Incorporated
Gastric Cancer
The Effect of Dexmedetomidine During Opioid Free Anesthesia on Postoperative Recovery After Gastrectomy
"Want to know the effect of dexmedetomidine during opioid free anesthesia on postoperative recovery after gastrectomy. Patients undergoing open gastrectomy are divided into dexmedetomidine group and control(remifentanil) group…
- Trial name
- NCT04529135
- Testing
- Dexmedetomidine, Remifentanil
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Gangnam Severance Hospital
Stomach Cancer, Gastro Esophageal Junction Cancer
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.
- Trial name
- PANDA (NCT03448835)
- Testing
- Atezolizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Gastric Cancer Stage, Esophageal Cancer
Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
Gastric retention not only compromises the quality of endoscopic examination but also significantly increases the risk of reflux and aspiration in sedated patients.
- Conditions
- Gastric Cancer Stage, Esophageal Cancer, Gastroparesis
- Trial name
- NCT07104214
- Where
- 3 sites in China
- Volunteers
- 5,000 people
- Sponsor
- Zhejiang University
Gastric Cancer, Esophageal Cancer
Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care
Clinical Decision Support Systems (CDSSs) to augment clinical care and decision making. These are platforms which aim to improve healthcare delivery by enhancing medical decisions with targeted clinical knowledge, patient…
- Conditions
- Gastric Cancer, Esophageal Cancer, Esophagogastric Junction Cancer
- Trial name
- NCT04675138
- Testing
- No intervention will be provided to the subject
- Where
- 9 sites in Germany, Japan and 4 more
- Volunteers
- 1,000 people
- Sponsor
- National University Hospital, Singapore
Helicobacter Pylori Infection
Community-based Helicobacter Pylori Eradication
Based on a universal eradication of H. pylori in an offshore island (Matsu) with a high prevalence of gastric cancer as well as premalignant gastric lesion, we first examined the infection rate of H. pylori.
- Trial name
- NCT00155389
- Testing
- Helicobacter pylori eradication
- Where
- 2 sites in Taiwan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Stomach Neoplasms
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
- Trial name
- NCT00553696
- Testing
- Cisplatin, S-1, Sunitinib
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Pfizer
Stomach Neoplasms
Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
Randomized phase II study designed to evaluate the efficacy and safety of continuous S-1 plus oxaliplatin versus intermittent S-1 plus oxaliplatin as first-line therapy in patients with recurrent and/or metastastic gastric…
- Trial name
- NCT00515190
- Testing
- S-1,oxaliplatin
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- National Cancer Center, Korea
Gastric Cancer, Colorectal Cancer
Status of Management of Surgery in Beijing During COVID-19
This is a multi-centered, retrospective, observational study aimed at observing the current status of the management of gastrointestinal surgery during the COVID-19 pandemic, particularly the changes on surgery protocols and…
- Conditions
- Gastric Cancer, Colorectal Cancer, Gastrointestinal Disease
- Trial name
- NCT04401124
- Testing
- no intervention
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually…
- Conditions
- Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT02831179
- Testing
- Capecitabine, Temozolomide, Veliparib
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line…
- Trial name
- JACOB (NCT01774786)
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 172 sites in United States, Australia and 30 more
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Gastric Adenocarcinoma, Gastric Cancer
Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients
Surgical manipulation and handling of a tumor may cause dissemination of cancer cells through peritoneal cavity after curative gastrectomy.
- Trial name
- NCT02287168
- Testing
- pre-gastrectomy peritoneal washing cytology, post-gastrectomy peritoneal washing cytology, post-lavage peritoneal washing cytology
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Bezmialem Vakif University
Gastric Cancer
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction (GEJ) who have not previously received…
- Trial name
- NCT01388790
- Testing
- Cetuximab, Cisplatin, S-1
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, KRAS Mutation
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06056024
- Testing
- BI 3706674
- Where
- 17 sites in United States, Japan and 2 more
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression
- Trial name
- NCT07446049
- Testing
- CVL237 tablets
- Volunteers
- 180 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Gastrectomy, Gastric Carcinoma
The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery
The northwest Chinese population has unique anatomical characteristics of splenic artery due to ethnic differences, which has an important impact on the development and prognosis of laparoscopic radical total gastrectomy.
- Trial name
- NCT06680362
- Where
- China
- Volunteers
- 176 people
- Sponsor
- xiaohua li